Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, Wechalekar AD, Berk JL, Quarta CC, Grogan M, Lachmann HJ, Bokhari S, Castano A, Dorbala S, Johnson GB, Glaudemans AW, Rezk T, Fontana M, Palladini G, Milani P, Guidalotti PL, Flatman K, Lane T, Vonberg FW, Whelan CJ, Moon JC, Ruberg FL, Miller EJ, Hutt DF, Hazenberg BP, Rapezzi C, Hawkins PN. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133:2404–12.

Article  PubMed  CAS  Google Scholar 

Ahluwalia N, Roshankar G, Draycott L, Jimenez-Zepeda V, Fine N, Chan D, Han D, Miller RJH. Diagnostic accuracy of bone scintigraphy imaging for transthyretin cardiac amyloidosis: systematic review and meta-analysis. J Nucl Cardiol. 2023;30:2464–76.

Article  PubMed  Google Scholar 

Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, Leone O, Farsad M, Ciliberti P, Bacchi-Reggiani L, Fallani F, Branzi A, Rapezzi C. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005;46:1076–84.

Article  PubMed  Google Scholar 

Tafamidis Meglumine (Vyndaqel): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with cardiomyopathy due to transthyretin-mediated amyloidosis, wild type or hereditary, to reduce cardiovascular mortality and cardiovascular-related hospitalization [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022.

Caobelli F, Gözlügöl N, Bakula A, Rominger A, Schepers R, Stortecky S, Hunziker Munsch L, Dobner S, Gräni C. Prognostic value of [99mTc]Tc-DPD quantitative SPECT/CT in patients with suspected and confirmed amyloid Transthyretin-Related cardiomyopathy and preserved left ventricular function. J Nucl Med. 2024;65:944–51.

Martinez-Naharro A, Treibel TA, Abdel-Gadir A, Bulluck H, Zumbo G, Knight DS, Kotecha T, Francis R, Hutt DF, Rezk T, Rosmini S, Quarta CC, Whelan CJ, Kellman P, Gillmore JD, Moon JC, Hawkins PN, Fontana M. Magnetic resonance in transthyretin cardiac amyloidosis. J Am Coll Cardiol. 2017;70:466–77.

Article  PubMed  CAS  Google Scholar 

Caobelli F, Braun M, Haaf P, Wild D, Zellweger MJ. Quantitative 99mTc-DPD SPECT/CT in patients with suspected ATTR cardiac amyloidosis: feasibility and correlation with visual scores. J Nucl Cardiol. 2020;27:1456–63.

Dorbala S, Park MA, Cuddy S, Singh V, Sullivan K, Kim S, Falk RH, Taqueti VR, Skali H, Blankstein R, Bay C, Kijewski MF, Di Carli MF. Absolute quantitation of cardiac 99mTc-Pyrophosphate using Cadmium-Zinc-Telluride-Based SPECT/CT. J Nucl Med. 2021;62:716–22.

Ben-Haim S, Chicheportiche A, Goshen E, Arad M, Smekhov M, Menezes LJ, Elliott PM, O’Mahoney E, Stern E, Yuzefovich B, Bomanji JB. Quantitative SPECT/CT parameters of myocardial 99mTechnetium-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) uptake in suspected cardiac transthyretin amyloidosis. EJNMMI Res. 2021;11:86.

Hutt DF, Fontana M, Burniston M, Quigley AM, Petrie A, Ross JC, Page J, Martinez-Naharro A, Wechalekar AD, Lachmann HJ, Quarta CC, Rezk T, Mahmood S, Sachchithanantham S, Youngstein T, Whelan CJ, Lane T, Gilbertson JA, Rowczenio D, Hawkins PN, Gillmore JD. Prognostic utility of the perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid. Eur Heart J Cardiovasc Imaging. 2017;18:1344–50.

Article  PubMed  Google Scholar 

Salvalaggio A, Cipriani A, Righetto S, Artioli P, Sinigiani G, De Michieli L, Cason M, Pilichou K, Cecchin D, Briani C. Incidental cardiac uptake of 99mTc-diphosphonates is predictive of poor outcome: data from 9616 bone scintigraphies. J Nucl Cardiol. 2022;29:3419–25.

Maurer MS, Bokhari S, Damy T, Dorbala S, Drachman BM, Fontana M, Grogan M, Kristen AV, Lousada I, Nativi-Nicolau J, Cristina Quarta C, Rapezzi C, Ruberg FL, Witteles R, Merlini G. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circ Heart Fail. 2019;12:e006075.

Article  PubMed  PubMed Central  Google Scholar 

Hutt DF, Quigley AM, Page J, Hall ML, Burniston M, Gopaul D, Lane T, Whelan CJ, Lachmann HJ, Gillmore JD, Hawkins PN, Wechalekar AD. Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. Eur Heart J Cardiovasc Imaging. 2014;15:1289–98.

Article  PubMed  Google Scholar 

Haaf P, Garg P, Messroghli DR, Broadbent DA, Greenwood JP, Plein S. Cardiac T1 mapping and extracellular volume (ECV) in clinical practice: a comprehensive review. J Cardiovasc Magn Reson. 2016;18:89.

Article  PubMed  PubMed Central  Google Scholar 

Knight DS, Zumbo G, Barcella W, Steeden JA, Muthurangu V, Martinez-Naharro A, Treibel TA, Abdel-Gadir A, Bulluck H, Kotecha T, Francis R, Rezk T, Quarta CC, Whelan CJ, Lachmann HJ, Wechalekar AD, Gillmore JD, Moon JC, Hawkins PN, Fontana M. Cardiac structural and functional consequences of amyloid deposition by cardiac magnetic resonance and echocardiography and their prognostic roles. JACC Cardiovasc Imaging. 2019;12:823–33.

Article  PubMed  Google Scholar 

Martinez-Naharro A, Treibel TA, Abdel-Gadir A, Bulluck H, Zumbo G, Knight DS, Kotecha T, Francis R, Hutt DF, Rezk T, Rosmini S, Quarta CC, Whelan CJ, Kellman P, Gillmore JD, Moon JC, Hawkins PN, Fontana M. Magnetic resonance in transthyretin cardiac amyloidosis. J Am Coll Cardiol. 2017;70(4):466–77. https://doi.org/10.1016/j.jacc.2017.05.053.

Article  PubMed  CAS  Google Scholar 

Rettl R, Mann C, Duca F, Dachs TM, Binder C, Ligios LC, Schrutka L, Dalos D, Koschutnik M, Donà C, Kammerlander A, Beitzke D, Loewe C, Charwat-Resl S, Hengstenberg C, Kastner J, Eslam RB, Bonderman D. Tafamidis treatment delays structural and functional changes of the left ventricle in patients with transthyretin amyloid cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2022;23:767–80.

Article  PubMed  Google Scholar 

Rettl R, Calabretta R, Duca F, Binder C, Kronberger C, Willixhofer R, Poledniczek M, Donà C, Nitsche C, Beitzke D, Loewe C, Auer-Grumbach M, Bonderman D, Kastl S, Hengstenberg C, Badr Eslam R, Kastner J, Bergler-Klein J, Hacker M, Kammerlander A. Reduction in 99mTc-DPD myocardial uptake with therapy of ATTR cardiomyopathy. Amyloid. 2024;31:42–51.

Rettl R, Wollenweber T, Duca F, Binder C, Cherouny B, Dachs TM, Camuz Ligios L, Schrutka L, Dalos D, Beitzke D, Loewe C, Badr Eslam R, Kastner J, Hacker M, Bonderman D. Monitoring Tafamidis treatment with quantitative SPECT/CT in transthyretin amyloid cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2023;24:1019–30.

Article  PubMed  PubMed Central  Google Scholar 

Papathanasiou M, Kessler L, Bengel FM, Jakstaite AM, Kersting D, Varasteh Z, Luedike P, Carpinteiro A, Herrmann K, Rassaf T, Rischpler C. Regression of myocardial 99mTc-DPD uptake after Tafamidis treatment of cardiac transthyretin amyloidosis. J Nucl Med. 2023;64:1083–6.

Vijayakumar S, Pabon AR, Clerc OF, Cuddy SAM, Gu Y, Watts C, Sullivan K, Auer B, Kijewski MF, DiCarli MF, Falk RH, Dorbala S. Quantitative 99mTc-pyrophosphate myocardial uptake: changes on transthyretin stabilization therapy. J Nucl Cardiol. 2024;39:102019. https://doi.org/10.1016/j.nuclcard.2024.102019.

Caobelli F. Recent evidence on cardiac 99mTc-DPD uptake after therapy with Tafamidis May reveal the road to an Ultra-Early diagnosis in patients with ATTR amyloidosis. J Nucl Med. 2024;65:329.